Serum acute phase reactants hallmark healthy individuals at risk for acetaminophen-induced liver injury

Genome Medicine

Volumn 5, Issue 9, 2013, Pages

  Borlak, Jürgen ^a   Chatterji, Bijon ^a   Londhe, Kishor B ^a   Watkins, Paul B ^b  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b HAMNER INSTITUTES FOR HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE PHASE PROTEIN; ALANINE AMINOTRANSFERASE; ALPHA 1 ANTITRYPSIN; C REACTIVE PROTEIN; ENZYME PRECURSOR; HAPTOGLOBIN; HEMOPEXIN; KININOGEN; PARACETAMOL; PLACEBO; PLASMINOGEN; RETINOL BINDING PROTEIN; SERUM AMYLOID A; TRANSTYRETIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; DRUG INDUCED DISEASE; FEMALE; HUMAN; IMMUNE RESPONSE; IMMUNOASSAY; INFLAMMATION; LIVER CELL; LIVER INJURY; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEOMICS; SPUTUM ANALYSIS;

EID: 84884614332     PISSN: None     EISSN: 1756994X     Source Type: Journal    
DOI: 10.1186/gm493     Document Type: Article

References (44)

1. Maddrey WC. Drug-induced hepatotoxicity: 2005. J Clin Gastroenterol 2005, 39:S83-S89. 10.1097/01.mcg.0000155548.91524.6e, 15758665.
2. Senior JR. Drug hepatotoxicity from a regulatory perspective. Clin Liver Dis 2007, 11:507-524. 10.1016/j.cld.2007.06.002, 17723917.
3. Reuben A, Koch DG, Lee WM. Acute Liver Failure Study Group Drug-induced acute liver failure: results of a U.S. multicenter, prospective study. Hepatology 2010, 52:2065-2076. 10.1002/hep.23937, 20949552, Acute Liver Failure Study Group.
4. Zimmerman HJ. Drug-induced liver disease. Clin Liver Dis 2000, 4:73-96. vi, 10.1016/S1089-3261(05)70097-0, 11232192.
5. Ostapowicz G, Fontana RJ, Schiodt FV, Larson A, Davern TJ, Han SH, McCashland TM, Shakil AO, Hay JE, Hynan L, Crippin JS, Blei AT, Samuel G, Reisch J, Lee WM. U.S. Acute Liver Failure Study Group Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med 2002, 137:947-954. 10.7326/0003-4819-137-12-200212170-00007, 12484709, U.S. Acute Liver Failure Study Group.
6. Olson H, Betton G, Robinson D, Thomas K, Monro A, Kolaja G, Lilly P, Sanders J, Sipes G, Bracken W, Dorato M, Van Deun K, Smith P, Berger B, Heller A. Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul Toxicol Pharmacol 2000, 32:56-67. 10.1006/rtph.2000.1399, 11029269.
7. Ballet F. Back to basics for idiosyncratic drug-induced liver injury: dose and metabolism make the poison. Gastroenterol Clin Biol 2010, 34:348-350. 10.1016/j.gcb.2010.04.015, 20576380.
8. Walgren JL, Mitchell MD, Thompson DC. Role of metabolism in drug-induced idiosyncratic hepatotoxicity. Crit Rev Toxicol 2005, 35:325-361. 10.1080/10408440590935620, 15989140.
9. Uetrecht JP. New concepts in immunology relevant to idiosyncratic drug reactions: the 'danger hypothesis' and innate immune system. Chem Res Toxicol 1999, 12:387-395. 10.1021/tx980249i, 10328748.
10. Urban TJ, Shen Y, Stolz A, Chalasani N, Fontana RJ, Rochon J, Ge D, Shianna KV, Daly AK, Lucena MI, Nelson MR, Molokhia M, Aithal GP, Floratos A, Pe'er I, Serrano J, Bonkovsky H, Davern TJ, Lee WM, Navarro VJ, Talwalkar JA, Goldstein DB, Watkins PB. Drug-Induced Liver Injury Network, DILIGEN, EUDRAGENE, Spanish DILI Registry, International Serious Adverse Events Consortium Limited contribution of common genetic variants to risk for liver injury due to a variety of drugs. Pharmacogenet Genomics 2012, 22:784-795. 10.1097/FPC.0b013e3283589a76, 3636716, 22968431, Drug-Induced Liver Injury Network, DILIGEN, EUDRAGENE, Spanish DILI Registry, International Serious Adverse Events Consortium.
11. Watkins PB, Kaplowitz N, Slattery JT, Colonese CR, Colucci SV, Stewart PW, Harris SC. Aminotransferase elevations in healthy adults receiving 4 grams of acetaminophen daily: a randomized controlled trial. JAMA 2006, 296:87-93. 10.1001/jama.296.1.87, 16820551.
12. Winnike JH, Li Z, Wright FA, Macdonald JM, O'Connell TM, Watkins PB. Use of pharmaco-metabonomics for early prediction of acetaminophen-induced hepatotoxicity in humans. Clin Pharmacol Ther 2010, 88:45-51. 10.1038/clpt.2009.240, 20182423.
13. Uehara T, Ono A, Maruyama T, Kato I, Yamada H, Ohno Y, Urushidani T. The Japanese toxicogenomics project: application of toxicogenomics. Mol Nutr Food Res 2010, 54:218-227. 10.1002/mnfr.200900169, 20041446.
14. Chatterji B, Borlak J. A 2-DE MALDI-TOF study to identify disease regulated serum proteins in lung cancer of c-myc transgenic mice. Proteomics 2009, 9:1044-1056. 10.1002/pmic.200701135, 19180532.
15. Larson AM, Polson J, Fontana RJ, Davern TJ, Lalani E, Hynan LS, Reisch JS, Schiodt FV, Ostapowicz G, Shakil AO, Lee WM. Acute Liver Failure Study Group Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study. Hepatology 2005, 42:1364-1372. 10.1002/hep.20948, 16317692, Acute Liver Failure Study Group.
16. Inatsu A, Kinoshita M, Nakashima H, Shimizu J, Saitoh D, Tamai S, Seki S. Novel mechanism of C-reactive protein for enhancing mouse liver innate immunity. Hepatology 2009, 49:2044-2054. 10.1002/hep.22888, 19444871.
17. Chen W, Lu H, Dutt K, Smith A, Hunt DM, Hunt RC. Expression of the protective proteins hemopexin and haptoglobin by cells of the neural retina. Exp Eye Res 1998, 67:83-93. 10.1006/exer.1998.0494, 9702181.
18. Fagoonee S, Gburek J, Hirsch E, Marro S, Moestrup SK, Laurberg JM, Christensen EI, Silengo L, Altruda F, Tolosano E. Plasma protein haptoglobin modulates renal iron loading. Am J Pathol 2005, 166:973-983. 10.1016/S0002-9440(10)62319-X, 1602399, 15793279.
19. Lisi S, Gamucci O, Vottari T, Scabia G, Funicello M, Marchi M, Galli G, Arisi I, Brandi R, D'Onofrio M, Pinchera A, Santini F, Maffei M. Obesity-associated hepatosteatosis and impairment of glucose homeostasis are attenuated by haptoglobin deficiency. Diabetes 2011, 60:2496-2505. 10.2337/db10-1536, 3178294, 21873550.
20. Bell LN, Theodorakis JL, Vuppalanchi R, Saxena R, Bemis KG, Wang M, Chalasani N. Serum proteomics and biomarker discovery across the spectrum of nonalcoholic fatty liver disease. Hepatology 2010, 51:111-120. 10.1002/hep.23271, 2903216, 19885878.
21. Izumi S, Hughes RD, Langley PG, Pernambuco JR, Williams R. Extent of the acute phase response in fulminant hepatic failure. Gut 1994, 35:982-986. 10.1136/gut.35.7.982, 1374848, 8063228.
22. Rosen HR. Liver disease associated with alpha1-antitrypsin deficiency. Clin Liver Dis 1998, 2:175-185. 10.1016/S1089-3261(05)70370-6, 15560052.
23. Bell LN, Vuppalanchi R, Watkins PB, Bonkovsky HL, Serrano J, Fontana RJ, Wang M, Rochon J, Chalasani N. US Drug-Induced Liver Injury Network (DILIN) Research Group Serum proteomic profiling in patients with drug-induced liver injury. Aliment Pharmacol Ther 2012, 35:600-612. 10.1111/j.1365-2036.2011.04982.x, 3654532, 22403816, US Drug-Induced Liver Injury Network (DILIN) Research Group.
24. Merrick BA, Bruno ME, Madenspacher JH, Wetmore BA, Foley J, Pieper R, Zhao M, Makusky AJ, McGrath AM, Zhou JX, Taylor J, Tomer KB. Alterations in the rat serum proteome during liver injury from acetaminophen exposure. J Pharmacol Exp Ther 2006, 318:792-802. 10.1124/jpet.106.102681, 1892200, 16687475.
25. Fleming RE, Whitman IP, Gitlin JD. Induction of ceruloplasmin gene expression in rat lung during inflammation and hyperoxia. Am J Physiol 1991, 260:L68-L74.
26. Zhang AS, Xiong S, Tsukamoto H, Enns CA. Localization of iron metabolism-related mRNAs in rat liver indicate that HFE is expressed predominantly in hepatocytes. Blood 2004, 103:1509-1514.
27. Wakamiya M, Blackburn MR, Jurecic R, McArthur MJ, Geske RS, Cartwright J, Mitani K, Vaishnav S, Belmont JW, Kellems RE. Disruption of the adenosine deaminase gene causes hepatocellular impairment and perinatal lethality in mice. Proc Natl Acad Sci USA 1995, 92:3673-3677. 10.1073/pnas.92.9.3673, 42023, 7731963.
28. Migchielsen AA, Breuer ML, van Roon MA, te Riele H, Zurcher C, Ossendorp F, Toutain S, Hershfield MS, Berns A, Valerio D. Adenosine-deaminase-deficient mice die perinatally and exhibit liver-cell degeneration, atelectasis and small intestinal cell death. Nat Genet 1995, 10:279-287. 10.1038/ng0795-279, 7670465.
29. Bollinger ME, Arredondo-Vega FX, Santisteban I, Schwarz K, Hershfield MS, Lederman HM. Brief report: hepatic dysfunction as a complication of adenosine deaminase deficiency. N Engl J Med 1996, 334:1367-1371. 10.1056/NEJM199605233342104, 8614422.
30. Pratibha K, Usha A, Rajni A. Serum adenosine deaminase, 5′ nucleotidase and malondialdehyde in acute infective hepatitis. IJCB 2004, 19:128-131. 3454215, 23105470.
31. Marilena G. New physiological importance of two classic residual products: carbon monoxide and bilirubin. Biochem Mol Med 1997, 61:136-142. 10.1006/bmme.1997.2610, 9259978.
32. Spielberg SP, Gordon GB. Glutathione synthetase-deficient lymphocytes and acetaminophen toxicity. Clin Pharmacol Ther 1981, 29:51-55. 10.1038/clpt.1981.9, 7460474.
33. Kawao N, Nagai N, Okada K, Okumoto K, Ueshima S, Matsuo O. Role of plasminogen in macrophage accumulation during liver repair. Thromb Res 2010, 125:e214-e221. 10.1016/j.thromres.2009.12.009, 20064655.
34. Kawao N, Nagai N, Ishida C, Okada K, Okumoto K, Suzuki Y, Umemura K, Ueshima S, Matsuo O. Plasminogen is essential for granulation tissue formation during the recovery process after liver injury in mice. J Thromb Haemost 2010, 8:1555-1566. 10.1111/j.1538-7836.2010.03870.x, 20345714.
35. Ganey PE, Luyendyk JP, Newport SW, Eagle TM, Maddox JF, Mackman N, Roth RA. Role of the coagulation system in acetaminophen-induced hepatotoxicity in mice. Hepatology 2007, 46:1177-1186. 10.1002/hep.21779, 17654741.
36. Sullivan BP, Kassel KM, Jone A, Flick MJ, Luyendyk JP. Fibrin(ogen)-independent role of plasminogen activators in acetaminophen-induced liver injury. Am J Pathol 2012, 180:2321-2329. 10.1016/j.ajpath.2012.02.011, 3378852, 22507835.
37. Cordova C, Violi F, Alessandri C, Ferro D, Saliola M, Balsano F. Hageman factor, high molecular weight kininogen, and prekallikrein in chronic liver disease. J Clin Pathol 1986, 39:1003-1005. 10.1136/jcp.39.9.1003, 500201, 3639088.
38. de Toledo CF, Borges DR. Plasma-kallikrein clearance by the liver of acetaminophen-intoxicated rats. Life Sci 1993, 52:1451-1459. 10.1016/0024-3205(93)90069-F, 8464345.
39. Zhu X, Parks JS. New roles of HDL in inflammation and hematopoiesis. Annu Rev Nutr 2012, 32:161-182. 10.1146/annurev-nutr-071811-150709, 22540255.
40. Panduro A, Lin-Lee YC, Chan L, Shafritz DA. Transcriptional and posttranscriptional regulation of apolipoprotein E, A-I, and A-II gene expression in normal rat liver and during several pathophysiologic states. Biochemistry 1990, 29:8430-8435. 10.1021/bi00488a033, 2123716.
41. Trentalance A, Bruscalupi G, Conti Devirgiliis L, Leoni S, Mangiantini MT, Rossini L, Spagnuolo S, Erickson SK. Changes in lipoprotein binding and uptake by hepatocytes during rat liver regeneration. Biosci Rep 1989, 9:231-241. 10.1007/BF01116000, 2548637.
42. DeKroon RM, Mihovilovic M, Goodger ZV, Robinette JB, Sullivan PM, Saunders AM, Strittmatter WJ. ApoE genotype-specific inhibition of apoptosis. J Lipid Res 2003, 44:1566-1573. 10.1194/jlr.M300097-JLR200, 12754278.
43. Wozniak MA, Itzhaki RF, Faragher EB, James MW, Ryder SD, Irving WL. Trent HCV Study Group Apolipoprotein E-epsilon 4 protects against severe liver disease caused by hepatitis C virus. Hepatology 2002, 36:456-463. 10.1053/jhep.2002.34745, 12143056, Trent HCV Study Group.
44. Goubern M, Andriamihaja M, Nubel T, Blachier F, Bouillaud F. Sulfide, the first inorganic substrate for human cells. FASEB J 2007, 21:1699-1706. 10.1096/fj.06-7407com, 17314140.